Lista de obras -

Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.

artículo científico publicado en 2017

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

artículo científico publicado en 2018

B cells and tertiary lymphoid structures promote immunotherapy response

artículo científico publicado en 2020

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy

scientific article published on 22 November 2018

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

artículo científico publicado en 2017

Combining checkpoint inhibition and targeted therapy in melanoma

scientific article published on 01 June 2019

Comprehensive analysis of cutaneous and uveal melanoma liver metastases

artículo científico publicado en 2020

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

artículo científico publicado en 2018

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

artículo científico publicado en 2019

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

scientific article published on 27 December 2018

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

scientific article published on 01 April 2020

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

scientific article published on 26 February 2019

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls

artículo científico publicado en 2020

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

artículo científico publicado en 2017

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

artículo científico publicado en 2019

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

artículo científico publicado en 2018

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

scientific article published on 01 July 2019

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

artículo científico publicado en 2018

Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies

artículo científico publicado en 2016

Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)

artículo científico publicado en 2020

Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers

artículo científico publicado en 2019

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4

scientific article published on 06 July 2021

Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy

scientific article published on 01 October 2019

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance

scientific article published on 07 August 2020

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience

artículo científico publicado en 2017

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma

scientific article published on 18 March 2019

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events

scientific article published on 21 July 2019

Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma

artículo científico publicado en 2019

Targeting tumor-associated acidity in cancer immunotherapy

artículo científico publicado en 2018

The human tumor microbiome is composed of tumor type-specific intracellular bacteria

artículo científico publicado en 2020

Lista de obras de

Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

B cells and tertiary lymphoid structures promote immunotherapy response

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

Combining checkpoint inhibition and targeted therapy in melanoma

Comprehensive analysis of cutaneous and uveal melanoma liver metastases

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies

Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)

Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4

Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events

Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma

Targeting tumor-associated acidity in cancer immunotherapy

The human tumor microbiome is composed of tumor type-specific intracellular bacteria